Antigen-experienced T cells express high levels of immune checkpoint proteins, including programmed cell death-1 (PD-1) receptor. Preclinical and clinical data support the role of PD-1 and its ligand, programmed cell death ligand 1 (PD-L1) in cancer immunotherapy. AB122 is an anti-PD-1 monoclonal antibody that is being evaluated in a dose-escalation monotherapy study as well as in combination with AB928, a potent small molecule inhibitor of the adenosine 2 receptor (A2R). In both studies, PD-1 receptor occupancy (RO) on T cells was determined. A small but significant number of these T cells can recognize neo-epitopes (neoE) arising from patient specific mutations.

Materials and Methods

Determination of PD-1 Receptor Occupancy (RO): Total CD3+ lymphocytes, CD3+CD8+ cytotoxic T-cells and CD3+CD8+ cytotoxic T-cells and CD3+CD8+ CD4+ (CD4 T-cells) were identified by surface staining using flow cytometry. Within the T-cell subsets, PD-1 receptor occupancy was determined from isolated, cryopreserved peripheral blood mononuclear cells (PBMCs) or using whole blood (WB). Two methods were: 1) saturation binding using a biotinylated anti-hiP34 for the detection of AB122 (previously published method) and 2) direct competition using a commercially available anti-PD-1 antibody (Figure 2).

Evaluation of Proliferation: T-cell proliferation in cancer patients following dosing with AB122 was determined as a function of the frequency of Ki-67+ cells. Intra-cellular staining was performed on both isolated PBMCs as well as whole blood post-RBC lysis and fixation.

Patient-Specific NeoE-Targeted CDB T Cells

### Results – PD-1 Receptor Occupancy

**Figure 3.** PD-1 receptor occupancy determined on PBMCs using the competitive antibody method in AB122-dosed subjects in the dose-escalation phase. Three dosing regimens were evaluated: Subjects A-C (80 mg Q2W), subjects D-I (240 mg Q2W) and subjects J and K (360 mg Q2W). Comparable PD-1 receptor occupancy data were obtained using the previously published saturation binding method on total CD3+ lymphocytes and the individual T-cell subsets (data not shown). Red arrows indicate AB122 dosing.

**Figure 4.** Comparable PD-1 receptor occupancy on T-cell subsets in whole blood was observed in an ongoing AB928 dose-escalation + AB122 combination trial. All subjects received 240 mg Q2W of AB122. Subjects also received once daily dosing of AB928: Subjects L and M (75 mg AB928) and subjects N and O (150 mg AB928).

**Frequency of Ki-67+ Cells Varies Among Subjects When Comparing Baseline to 15 Days Post-AB122 Administration**

**Figure 5.** Representative flow cytometry plots for the identification of T-cell subsets and their respective frequencies of Ki-67+ cells in AB122-dosed patients (top panel). Frequency of Ki-67+ cells within the CD8+ and CD4+ (identified as CD3+CD8+) lymphocyte subsets was determined on all subjects shown at baseline (day 1) and 15 days following AB122 administration. Data are represented as a fold change in the frequency of cells between the two timepoints (bottom plot). Subjects A-C (80 mg Q2W), subjects D-I (240 mg Q2W) and subjects J and K (360 mg Q2W).

### Results – NeoE Epitope (NeoE)-Specific T Cells

**Figure 6.** Evolution of NeoE-specific T-cell response to AB122 (anti-PD1) treatment, showing drug-dependent target-specific expansion, as captured from patient blood using PACT Pharma’s imPACT™ isolation technology. Tumor-exclusive NeoE-HLA candidates are displayed by highest to lowest predicted binding affinity (bottom plot, x-axis) as well as the clonality/prevalence of tumor cells expressing the mutated neoantigen (y-axis, bottom plot). Green circles represent clonal mutations; red circles indicate sub-clonal neoantigen mutations. Identity/quantitation of T cells that are verified by capture from peripheral blood to recognize different NeoE-HLA candidates is shown (top three plots): TANC1: Tetraciclosporide repeat, ankyrin repeat and coiled-coil-domain containing protein 1, KIF21B: Kinesin Family Member 21B, PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, HIG2DA: HIG1 Hoxanoid Inducible Domain Family Member 2A. Please refer to abstract #4058 for additional data on neoE-specific T cells from peripheral blood or tumors from patients with different cancers using the imPACT™ technology.

Phenotypic Characterization of NeoE-Specific T cells in Peripheral Blood Using imPACT™

**Figure 7.** Representative flow cytometry plots characterizing individually captured NeoE-specific T cells (colored dots in plots correspond to imPACT-captured T cells in Fig 6). Evidence that neoE-specific T cells from peripheral blood are antigen-experienced (effector (‘D’), effector memory (‘C’); left plot) and those T cells that potentially also trafficked to the tumor (CD39 / CD103, right plot).

### Conclusions

- AB122 exhibited complete PD-1 receptor occupancy on peripheral T cells at all dose levels of the monotherapy dose-escalation study with a dosing regimen of Q2W (ns 11).
- Complete PD-1 receptor occupancy with AB122 was not impacted in a dose-escalation study of AB122 in combination with AB28 (Adenosine receptor antagonist).
- Patient-specific baseline levels and subsequent modulation post-AB122 of Ki-67+ cells was observed in all cohorts of the AB122 monotherapy trial.
- In collaboration with PACT Pharma, an expansion of patient-specific NeoE T cells was observed following AB122 administration.
- Longitudinal immune monitoring of neoE-specific T cells from blood by imPACT™ analysis holds potential to establish when and how patients respond to treatment with immunotherapy agents.

Interested in a career at Arcus? Visit www.arcusbio.com